Halpan-IV Injection contains Pantoprazole 40 mg, a proton pump inhibitor used for the treatment of acid-related gastrointestinal conditions. Pantoprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion. Halpan-IV is indicated for the short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and other pathological hypersecretory conditions. It is also utilized for the prevention and treatment of gastric ulcers, including those induced by nonsteroidal anti-inflammatory drugs (NSAIDs). Administered intravenously, Halpan-IV provides rapid and effective acid suppression, making it suitable for patients unable to take oral medication. The recommended dosage and duration of therapy should be determined by the physician based on the clinical condition of the patient. Common adverse effects may include headache, diarrhea, nausea, and abdominal pain, though the drug is generally well tolerated. Caution is advised in patients with hepatic impairment, and long-term use requires monitoring for potential vitamin B12 deficiency and hypomagnesemia. Halpan-IV Injection should be used under strict medical supervision to ensure optimal therapeutic outcomes and minimize risks.